Vascular endothelial growth factor receptor-3 is a favorable prognostic factor in advanced gastric carcinoma

Oncology Reports

Volumn 19, Issue 4, 2008, Pages 939-944

  Sung, Ji Youn ^a   Lee, Sun ^a   Kim, Youn Wha ^a   Park, Yong Koo ^a,b  

^a Kyung Hee University Hospital   (South Korea)

^b Medical Science and Engineering Research Center for Bioreaction to Reactive Oxygen Species   (South Korea)

Author keywords

Gastric carcinoma; Immunohistochemistry; Microarray; Prognosis; Vascular endothelial growth factor receptor 3

Indexed keywords

VASCULOTROPIN RECEPTOR 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH CARCINOMA; CHEMISTRY; CYTOPLASM; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 43849085210     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.4.939     Document Type: Article

References (30)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Adachi Y, Shiraishi N, Suematsu T, Shiromizu A, Yamaguchi K and Kitano S: Most important lymph node information in gastric cancer: multivariate prognostic study. Ann Surg Oncol 7: 503-507, 2000.
3. Karkkainen MJ and Petrova TV: Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19: 5598-5605, 2000.
4. Paavonen K, Puolakkainen P, Jussila L, Jahkola T and Alitalo K: Vascular endothelial growth factor receptor-3 in lymphangio-genesis in wound healing. Am J Pathol 156: 1499-1504, 2000.
5. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, Hung MC and Kuo ML: The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9: 209-223, 2006.
6. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T and Uchida Y: Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with non small cell lung carcinoma. Cancer 97: 457-464, 2003.
7. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J and Murray JC: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 62: 1669-1675, 2002.
8. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Sakamoto A, Sakamoto T, Maruyama H, Sato S, Mizunuma H and Smith SK: Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 9: 1361-1369, 2003.
9. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Umemoto M, Sakamoto T, Sato S, Mizunuma H and Smith SK: Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 88: 237-244, 2003.
10. Mylona E, Alexandrou P, Mpakali A, Giannopoulou I, Liapis G, Markaki S, Keramopoulos A and Nakopoulou L: Clinico-pathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol 33: 294-300, 2007.
11. Yang J, Wu HF, Qian LX, Zhang W, Hua LX, Yu ML, Wang Z, Xu ZQ, Sui YG and Wang XR: Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl 8: 169-175, 2006.
12. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP and Jacobs IJ: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201: 544-554, 2003.
13. Bando H, Weich HA, Horiguchi S, Funata N, Ogawa T and Toi M: The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncol Rep 15: 653-659, 2006.
14. Longatto Filho A, Martins A, Costa SM and Schmitt FC: VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract 201: 93-99, 2005.
15. O-charoenrat P, Rhys-Evans P and Eccles SA: Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556-568, 2001.
16. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y and Hirohashi S: Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6: 2431-2439, 2000.
17. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG and Morrow M: Stomach. In: AJCC cancer staging manual, Greene FL (ed.) Springer, New York, pp99-106, 2002.
18. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R and Alitalo K: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381-1390, 1999.
19. Saharinen P, Tammela T, Karkkainen MJ and Alitalo K: Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25: 387-395, 2004.
20. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F and Dammacco F: A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88: 176-185, 2003.
21. Aoki Y and Tosato G: Lymphatic regeneration: new insights from VEGFR-3 blockade. J Natl Cancer Inst 97: 2-3, 2005.
22. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW and Dana MR: Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med 10: 813-815, 2004.
23. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T and Alitalo K: Suppression of tumor lymphangio-genesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94: 819-825, 2002.
24. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K and Jooss K: Inhibition of lymphogenous metastasis using adenoassociated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65: 6901-6909, 2005.
25. Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, Kiss JZ, Dietrich PY, De Tribolet N, Pizzolato GP and Pepper MS: Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 209: 34-43, 2006.
26. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakudo K: Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 9: 5313-5317, 2003.
27. Yonemura Y, Fushida S, Bando E, Kinoshita K, Miwa K, Endo Y, Sugiyama K, Partanen T, Yamamoto H and Sasaki T: Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 37: 918-923, 2001.
28. Shida A, Fujioka S, Kobayashi K, Ishibashi Y, Nimura H, Mitsumori N and Yanaga K: Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol/Jpn Soc Clin Oncol 11: 38-43, 2006.
29. Borg JP, deLapeyriere O, Noguchi T, Rottapel R, Dubreuil P and Birnbaum D: Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase. Oncogene 10: 973-984, 1995.
30. Pajusola K, Aprelikova O, Armstrong E, Morris S and Alitalo K: Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 8: 2931-2937, 1993.